NCT01647919

Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: dsm-firmenich Switzerland AG · Industry
• Sex: All
• Age: 50 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to examine the efficacy of cogniVida™ on learning and memory performance (executive function, associative, spatial and verbal memory) as well as on mood and attention parameters after four, eight and eleven weeks of supplementation and in comparison with placebo. cogniVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The investigators do not claim that this supplement is meant to treat any ailment.

Conditions

• Healthy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	cogniVida™ 100 mg/day	4 capsules 25 mg (total 100 mg) cogniVida™ once a day
DIETARY_SUPPLEMENT	Placebo	4 capsules of placebo identical to cogniVida™ once a day

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2012-07-24
• Last updated: 2013-08-07

Locations

1 site across 1 country: United Kingdom